## HCA: HCA Healthcare, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -5.7% below STRENGTH zone (3.0-6.0%); PEG 1.22 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-1.6% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($444.37)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. HCA Healthcare to give $4.8m to support Pepperdine University’s nursing school**
- Source: Yahoo | 20251208T101200 | Bullish | Relevance: 99%
-  HCA Healthcare has committed $4.8 million to Pepperdine University’s School of Nursing to help address the national nursing shortage. This investment will support the development of a new 30,000-square-foot facility on the Calabasas campus, featuring advanced simulation laboratories. Students will also have opportunities for clinical rotations at HCA Healthcare’s Los Robles Regional Medical Center.

**2. California Public Employees Retirement System Has $124.64 Million Stock Position in HCA Healthcare, Inc. $HCA**
- Source: MarketBeat | 20251208T094854 | Bullish | Relevance: 99%
-  The California Public Employees' Retirement System (CalPERS) recently reduced its HCA Healthcare (NYSE:HCA) holdings by 5.4%, but still maintains a significant position worth approximately $124.64 million. This move comes as other institutional investors, such as Norges Bank and Price T Rowe Associates Inc. MD, have either initiated or significantly boosted their stakes in the company. HCA Healthcare reported strong Q3 earnings, surpassing analyst estimates, and announced a quarterly dividend, indicating healthy financial performance and a commitment to shareholder returns.

**3. State Street Corp Sells 191,043 Shares of HCA Healthcare, Inc. $HCA**
- Source: MarketBeat | 20251210T115530 | Neutral | Relevance: 99%
-  State Street Corp reduced its stake in HCA Healthcare, Inc. by 2.3% in the second quarter, selling 191,043 shares and now owning 7,956,663 shares valued at over $3 billion. Other institutional investors have also adjusted their positions, while an EVP at HCA Healthcare sold a significant number of shares in November. The article also provides financial details for HCA Healthcare, including recent earnings, dividends, and analyst ratings.

**4. Artificial Intelligence at HCA Healthcare – Two Use Cases**
- Source: Emerj Artificial Intelligence Research | 20251208T111621 | Bullish | Relevance: 98%
-  HCA Healthcare is leveraging AI in two key areas. First, they partnered with Google Cloud and Commure to implement generative AI for clinical documentation, aiming to improve workflow efficiency and free up clinicians' time. Second, they collaborated with GE HealthCare to develop CareIntellect for Perinatal, a cloud-based platform utilizing AI and predictive analytics to centralize maternal and fetal data, detect risks earlier, and strengthen perinatal outcomes.

**5. HCA Healthcare (NYSE: HCA) appoints Virginia Tenpenny to lead community engagement**
- Source: Stock Titan | 20251209T133231 | Bullish | Relevance: 98%
- HCA Healthcare has appointed Virginia Tenpenny as its new Vice President of Community Engagement, effective January 12, 2026. Tenpenny, who has over two decades of experience in corporate community impact, will lead the company's community engagement strategy, succeeding the retiring Joanne Pulles. This role oversees social and charitable investments, colleague giving, community outreach, and strategic partnerships.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-13 | Wells Fargo | $431 | $412 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-13 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($3.12M) |
| Sells | 4 ($14.79M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 29.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 7 |

**Top Holders:**
- Vanguard Group Inc: 6.5% (-3.8%)
- Blackrock Inc.: 5.5% (-3.7%)
- Sanders Capital, LLC: 4.7% (-3.9%)
- State Street Corpora: 3.3% (-5.9%)
- JPMORGAN CHASE & CO: 2.6% (+82.2%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-1.6% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $15M sold (4 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.22 suggests fair value with growth premium. Forward P/E 15.8x stretched relative to 8% growth. Quality metrics strong (ROE 136%, ROA 12%). Balance sheet: $3.1B free cash flow. Insider selling cluster ($14.8M in 90 days), potential headwind. Institutional flow bullish (2 buying vs 7 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $109.7B |
| Beta | 1.37 |
| 52W Range | $289.98 - $520.00 |
| Short Interest | 3.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.22 |
| Forward P/E | 15.8 |
| Current P/E | 17.0 |
| YoY Growth | 7.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -4.1% to -5.7% (-1.6% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 8.7pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.20x) but short-term weakness (below SMA20). MACD histogram bearish (-4.46), momentum weakening. RSI neutral at 43.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -5.72% (CS: 5) | Weak |
| RSI_14 | 42.9 | Neutral |
| MACD Histogram | -4.46 | Bearish |
| vs SMA20 | 0.960x | Below |
| vs SMA50 | 1.016x | Above |
| vs SMA200 | 1.201x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $468.73
- **Stop Loss:** $444.37 (5.2% risk)
- **Target:** $493.09 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 20
- **Position Value:** $9,374.60
- **Portfolio %:** 9.37%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with signs of improving risk appetite. Multiple major banks lowering prime rates suggest a dovish tilt in financial conditions ahead of the FOMC, while volatility remains subdued and breadth is moderate. Key drivers are easing lending rates, stable macro data, and improving sentiment, but selectivity is needed due to sector divergences.*

### Earnings

**Next:** 2026-01-23 (Est: $7.46)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.73 | $6.96 | +21.6% |
| 2025Q2 | $6.32 | $6.84 | +8.2% |
| 2025Q1 | $5.75 | $6.45 | +12.1% |
| 2024Q4 | $6.14 | $6.22 | +1.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*